Platelet-rich plasma for erectile dysfunction: a review of the current research landscape.

IF 3.6 2区 医学 Q1 UROLOGY & NEPHROLOGY
Dylan Fazekas, Katherine Campbell, Braian Ledesma, Thomas Masterson
{"title":"Platelet-rich plasma for erectile dysfunction: a review of the current research landscape.","authors":"Dylan Fazekas,&nbsp;Katherine Campbell,&nbsp;Braian Ledesma,&nbsp;Thomas Masterson","doi":"10.1093/sxmrev/qead032","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Erectile dysfunction (ED) is the inability to achieve or maintain erection for satisfactory sexual performance. ED drastically reduces the quality of life for men and their partners and is commonly linked to comorbid conditions such as diabetes and cardiovascular disease. As a result, clinicians and researchers are working to improve treatments for ED. Current guideline-approved ED treatments include oral phosphodiesterase type 5 inhibitors, intraurethral alprostadil, penile intracavernosal injections, and penile prosthesis surgery. Today, there is increasing interest in restorative therapies such as intracavernosal platelet-rich plasma (PRP) for the management of ED.</p><p><strong>Objectives: </strong>This narrative review describes the current trials investigating intracavernosal PRP for ED and proposes future directions to increase the strength of evidence to support use of PRP in this population.</p><p><strong>Methods: </strong>A comprehensive literature search of PubMed, Science Direct, and Scopus was performed to identify all randomized clinical trials using PRP for the treatment of ED.</p><p><strong>Results: </strong>We identified 4 randomized clinical trials investigating the safety and efficacy of PRP for ED. We found significant heterogeneity among study protocols, including collection of PRP, dosing of PRP, and follow-up.</p><p><strong>Conclusion: </strong>While intracavernosal PRP is considered safe, its efficacy for the management of ED remains unknown due to variability among clinical trials.</p>","PeriodicalId":21813,"journal":{"name":"Sexual medicine reviews","volume":null,"pages":null},"PeriodicalIF":3.6000,"publicationDate":"2023-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sexual medicine reviews","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/sxmrev/qead032","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Erectile dysfunction (ED) is the inability to achieve or maintain erection for satisfactory sexual performance. ED drastically reduces the quality of life for men and their partners and is commonly linked to comorbid conditions such as diabetes and cardiovascular disease. As a result, clinicians and researchers are working to improve treatments for ED. Current guideline-approved ED treatments include oral phosphodiesterase type 5 inhibitors, intraurethral alprostadil, penile intracavernosal injections, and penile prosthesis surgery. Today, there is increasing interest in restorative therapies such as intracavernosal platelet-rich plasma (PRP) for the management of ED.

Objectives: This narrative review describes the current trials investigating intracavernosal PRP for ED and proposes future directions to increase the strength of evidence to support use of PRP in this population.

Methods: A comprehensive literature search of PubMed, Science Direct, and Scopus was performed to identify all randomized clinical trials using PRP for the treatment of ED.

Results: We identified 4 randomized clinical trials investigating the safety and efficacy of PRP for ED. We found significant heterogeneity among study protocols, including collection of PRP, dosing of PRP, and follow-up.

Conclusion: While intracavernosal PRP is considered safe, its efficacy for the management of ED remains unknown due to variability among clinical trials.

富含血小板的血浆治疗勃起功能障碍:当前研究综述。
引言:勃起功能障碍(ED)是指无法实现或维持勃起以获得满意的性表现。ED大大降低了男性及其伴侣的生活质量,通常与糖尿病和心血管疾病等共病有关。因此,临床医生和研究人员正在努力改进ED的治疗方法。目前指南批准的ED治疗方法包括口服磷酸二酯酶5型抑制剂、尿道内前列地尔、阴茎腔内注射和阴茎假体手术。如今,人们对治疗ED的恢复性疗法越来越感兴趣,如腔内富血小板血浆(PRP)。目的:这篇叙述性综述描述了目前研究腔内富血小板等离子体治疗ED的试验,并提出了未来的方向,以增加支持在该人群中使用PRP的证据的强度。方法:对PubMed、Science Direct和Scopus进行全面的文献检索,以确定所有使用PRP治疗ED的随机临床试验。结果:我们确定了4项随机临床试验,研究PRP对ED的安全性和有效性。我们发现研究方案之间存在显著的异质性,包括PRP的收集、PRP的给药,结论:虽然腔内PRP被认为是安全的,但由于临床试验的可变性,其治疗ED的疗效仍然未知。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Sexual medicine reviews
Sexual medicine reviews UROLOGY & NEPHROLOGY-
CiteScore
7.60
自引率
8.30%
发文量
5
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信